IM Cannabis Corp. revenue

IM Cannabis Corp.'s revenue was $39.2m in fiscal 2025, down 0.7% on the year before. Since fiscal 2019 ($6.8m) it has grown at a compound 33.8% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

IM Cannabis Corp.: revenue history, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	7	12	27	42	36	39	39
Growth on the year before	—	+73.3%	+129.4%	+53.8%	−13.4%	+9.1%	−0.7%
Gross profit	3	8	5	7	7	6	7
Gross margin	43.3%	65.9%	18.6%	16.9%	20.2%	15.6%	17.7%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
IM Cannabis Corp.	$39.2m	-0.7%	—
Cumberland Pharmaceuticals Inc	$39.9m	-5.2%	-0.6%
BGM Group Ltd.	$37.9m	51.1%	—
Sunshine Biopharma Inc.	$35.3m	-2.7%	34.5%
Biofrontera Inc.	$46.2m	17.8%	16.7%
Scilex Holding Co	$31.6m	-28.5%	-12.0%

Compare with peers

Head to head: CPIX vs IMCC BGM vs IMCC IMCC vs SBFM BFRI vs IMCC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from IM Cannabis Corp.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to IM Cannabis Corp.